Faculty profile
Horacio Saragovi
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a McGill University directory, so their publications, courses and email address may be missing. Find their university profile.
Latest funding
- $1,071,000
Second-generation liquid biopsy diagnostic and prognostic tests selective for cancers expressing GD2 or GD3, and discovery of novel biomarkers in their extracellular vesicles
CIHR · 2025 · Nominated PI
- $1,290,555
Focused ultrasound-mediated regenerative strategies for Alzheimer's disease
CIHR · 2024 · Co-investigator
- $1,109,251
Development of effective targeted anti-GD2 cancer immunotherapies, that synergize with immune-checkpoint inhibitor blockades
CIHR · 2022 · Nominated PI
Second-generation liquid biopsy diagnostic and prognostic tests selective for cancers expressing GD2 or GD3, and discovery of novel biomarkers in their extracellular vesicles
Principal investigators: Saragovi, Horacio U
Keywords: Cancer; Diagnosis; Early Stage; Extracellular Vesicles; Genomics; Liquid Biopsy; Mass Spectrometry; Prognosis; Serum
Focused ultrasound-mediated regenerative strategies for Alzheimer's disease
Principal investigators: Aubert, Isabelle
Keywords: Alzheimer Disease; Brain Plasticity; Focused Ultrasound; Gene Therapy; Neurogenesis; Non-Invasive Delivery To The Brain; Oligodendrogenesis; Regeneration
Development of effective targeted anti-GD2 cancer immunotherapies, that synergize with immune-checkpoint inhibitor blockades
Principal investigators: Saragovi, Horacio U
Keywords: Adjuvant Therapy; Braf-Pten Mutation; Cancer Therapy; Combination Therapy; Gd2; Immune Checkpoint Inhibition; Melanoma; Monoclonal Antibody; Pd-1; Tumor Ganglioside
Innovation of Proprietary Liquid Biopsy Assays for Diagnosis of Early Stage Ovarian Cancer
Principal investigators: Saragovi, Horacio U
Keywords: Diagnostic; Elisa; Ganglioside; Immunohistochemistry,; Liquid Biopsy; Mass Spectrometry; Ovarian Cancer; Predictive; Prognostic; Tumor Marker
Innovation of a Proprietary Liquid Biopsy Strategy for Diagnosis of Early Stage Ovarian Cancer
Principal investigators: Saragovi, Horacio U
Keywords: Diagnostic; Elisa; Ganglioside; Immunohistochemistry; Liquid Biopsy; Mass Spectrometry; Ovarian Cancer; Predictive; Prognostic; Tumor Marker
Elucidating the paradox of TrkC receptor isoforms causing either neuronal survival or degeneration: target validation and therapeutic rationale using isoform-selective pharmacological and biological tools.
Principal investigators: Saragovi, Horacio U
Keywords: Agonist; Als; Antagonist; Cochlea; Hair Cells; Hearing Loss; Motor Neurons; Spinal Cord; Target Validation; Therapy
Therapy for motor neuron degeneration diseases targeting the opposing ligand-dependent signals of two TrkC receptor isoforms
Principal investigators: Saragovi, Horacio U
Keywords: Agonist; Als; Antagonist; Drug; Neurodegeneration; Neurotrophin; Receptor; Spinal Cord; Therapy
Brain degeneration and regeneration in preclinical models of Alzheimer's disease
Principal investigators: Aubert, Isabelle
Keywords: Aging; Alzheimer'S Disease; Drug Delivery; Gene Therapy; Mri-Guided Focused Ultrasound; Neurotrophins
Cancer vaccines targeting the ganglioside tumor-marker GD2
Principal investigators: Saragovi, Horacio U
Keywords: Biotechnology; Cancer; Vaccine
Neuroprotection in models of retinal ganglion cell death
Principal investigators: Saragovi, Horacio U
Keywords: Drug Development; Glaucoma; In Vivo Models Of Disease; Neuroprotection; Neurotoxicity; Neurotrophin; Receptor; Retina; Target Validation
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.